4D Molecular Therapeutics Other Current Liabilities

4D Molecular Therapeutics (FDMT) currently reports a other current liabilities of $23M as of March 2026. That compares with $12M in the prior-year period — up 89.7% year over year. Use the charts on this page to explore 4D Molecular Therapeutics's other current liabilities history and peer comparisons.

4D Molecular Therapeutics's other current liabilities increased from $12M to $23M — a 89.7% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

4D Molecular Therapeutics reported $23M in other current liabilities as of March 2026. That compares with $12M in the prior-year period — up 89.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $23M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for 4D Molecular Therapeutics, and consider following FDMT for alerts when major investors trade the stock.

4D Molecular Therapeutics is classified in the Healthcare sector. On other current liabilities, it currently shows $23M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FDMT with unrelated industries.